HLS Therapeutics Inc. Logo

HLS Therapeutics Inc.

HLTRF

(2.0)
Stock Price

2,53 USD

-44.09% ROA

-25.45% ROE

-3.55x PER

Market Cap.

85.841.100,00 USD

100.17% DER

0% Yield

-38.65% NPM

HLS Therapeutics Inc. Stock Analysis

HLS Therapeutics Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

HLS Therapeutics Inc. Fundamental Stock Analysis
# Analysis Rating
1 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

2 PBV

With a remarkably low PBV ratio (0.8x), the stock offers substantial upside potential at a bargain price.

3 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 DER

The stock has a reasonable amount of debt compared to its ownership (84%), suggesting a balanced financial position and a moderate level of risk.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

9 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-8) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

10 ROE

The stock's ROE indicates a negative return (-21.41%) on shareholders' equity, suggesting poor financial performance.

11 ROA

The stock's ROA (-54.29%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

HLS Therapeutics Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

HLS Therapeutics Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

HLS Therapeutics Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

HLS Therapeutics Inc. Revenue
Year Revenue Growth
1996 59.652.767
1997 76.240.391 21.76%
1998 101.319.295 24.75%
1999 95.627.377 -5.95%
2000 99.831.994 4.21%
2001 33.250.353 -200.24%
2002 35.519.693 6.39%
2003 83.213.677 57.32%
2004 77.808.741 -6.95%
2005 68.202.169 -14.09%
2006 49.661.118 -37.34%
2007 100.588.710 50.63%
2008 68.147.082 -47.61%
2009 71.875.656 5.19%
2010 88.098.904 18.41%
2011 78.746.327 -11.88%
2012 116.555.592 32.44%
2013 79.465.987 -46.67%
2014 73.877.125 -7.57%
2015 19.956.000 -270.2%
2016 53.381.197 62.62%
2017 75.082.000 28.9%
2018 61.415.000 -22.25%
2019 54.160.000 -13.4%
2020 56.109.000 3.47%
2021 60.009.000 6.5%
2022 61.467.000 2.37%
2023 65.668.000 6.4%
2023 64.230.702 -2.24%
2024 58.064.020 -10.62%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

HLS Therapeutics Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

HLS Therapeutics Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 2.206.000 100%
2016 6.663.000 66.89%
2017 11.877.000 43.9%
2018 14.463.000 17.88%
2019 18.090.000 20.05%
2020 18.485.000 2.14%
2021 17.397.000 -6.25%
2022 17.735.000 1.91%
2023 15.788.000 -12.33%
2023 8.390.000 -88.18%
2024 9.616.000 12.75%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

HLS Therapeutics Inc. EBITDA
Year EBITDA Growth
1996 1.409.704
1997 2.585.604 45.48%
1998 2.924.546 11.59%
1999 6.766.413 56.78%
2000 5.161.841 -31.09%
2001 5.726.511 9.86%
2002 5.624.937 -1.81%
2003 9.098.760 38.18%
2004 4.627.580 -96.62%
2005 6.279.490 26.31%
2006 3.247.254 -93.38%
2007 18.649.904 82.59%
2008 8.663.105 -115.28%
2009 11.005.634 21.28%
2010 11.530.155 4.55%
2011 22.291.870 48.28%
2012 29.192.927 23.64%
2013 18.679.151 -56.29%
2014 19.607.015 4.73%
2015 -2.465.969 895.1%
2016 -1.255.859 -96.36%
2017 55.661.000 102.26%
2018 21.439.000 -159.62%
2019 28.467.000 24.69%
2020 21.930.000 -29.81%
2021 24.024.000 8.72%
2022 20.962.000 -14.61%
2023 21.544.000 2.7%
2023 21.985.933 2.01%
2024 15.320.848 -43.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

HLS Therapeutics Inc. Gross Profit
Year Gross Profit Growth
1996 1.409.705
1997 2.585.605 45.48%
1998 2.924.547 11.59%
1999 6.766.413 56.78%
2000 5.161.842 -31.09%
2001 5.726.511 9.86%
2002 5.624.937 -1.81%
2003 9.098.761 38.18%
2004 4.627.581 -96.62%
2005 4.317.203 -7.19%
2006 3.207.790 -34.58%
2007 18.725.639 82.87%
2008 11.498.767 -62.85%
2009 10.665.648 -7.81%
2010 17.653.176 39.58%
2011 20.506.367 13.91%
2012 25.129.922 18.4%
2013 16.960.470 -48.17%
2014 20.848.336 18.65%
2015 20.170.745 -3.36%
2016 53.485.355 62.29%
2017 70.946.000 24.61%
2018 58.820.000 -20.62%
2019 52.228.000 -12.62%
2020 52.484.000 0.49%
2021 56.037.000 6.34%
2022 56.486.000 0.79%
2023 58.560.000 3.54%
2023 23.942.164 -144.59%
2024 25.434.752 5.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

HLS Therapeutics Inc. Net Profit
Year Net Profit Growth
1996 6.900.133
1997 1.747.030 -294.96%
1998 -6.628.973 126.35%
1999 4.073.657 262.73%
2000 2.288.074 -78.04%
2001 2.909.050 21.35%
2002 2.947.265 1.3%
2003 2.887.944 -2.05%
2004 -8.688.672 133.24%
2005 9.507.490 191.39%
2006 1.310.054 -625.73%
2007 7.594.668 82.75%
2008 -5.640.920 234.64%
2009 2.553.719 320.89%
2010 -733.883 447.97%
2011 11.983.349 106.12%
2012 16.867.203 28.95%
2013 9.732.618 -73.31%
2014 12.717.295 23.47%
2015 -1.732.375 834.1%
2016 -874.935 -98%
2017 -6.097.000 85.65%
2018 -24.806.000 75.42%
2019 -19.552.000 -26.87%
2020 -15.331.000 -27.53%
2021 -13.117.000 -16.88%
2022 -23.598.000 44.41%
2023 -37.748.000 37.49%
2023 -28.035.885 -34.64%
2024 -22.723.312 -23.38%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

HLS Therapeutics Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 1
1997 0 0%
1998 -1 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 1 0%
2012 1 0%
2013 0 0%
2014 1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 -1 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 -1 0%
2023 -1 100%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

HLS Therapeutics Inc. Free Cashflow
Year Free Cashflow Growth
1996 5.342.038
1997 -1.747.031 405.78%
1998 -5.719.114 69.45%
1999 -1.588.036 -260.14%
2000 5.601.952 128.35%
2001 1.786.320 -213.6%
2002 5.003.946 64.3%
2003 3.271.974 -52.93%
2004 984.077 -232.49%
2005 7.087.996 86.12%
2006 -17.175.704 141.27%
2007 10.588.709 262.21%
2008 -5.027.116 310.63%
2009 2.319.739 316.71%
2010 22.188.449 89.55%
2011 15.261.508 -45.39%
2012 19.207.301 20.54%
2013 17.539.938 -9.51%
2014 18.167.565 3.45%
2015 -3.102.462 685.59%
2016 -422.798 -633.79%
2017 26.987.000 101.57%
2018 31.966.000 15.58%
2019 23.849.000 -34.03%
2020 -35.333.000 167.5%
2021 11.919.000 396.44%
2022 6.794.000 -75.43%
2023 2.641.000 -157.25%
2023 14.501.144 81.79%
2024 1.849.222 -684.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

HLS Therapeutics Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 9.274.373
1997 5.520.614 -68%
1998 -64.990 8594.69%
1999 4.556.972 101.43%
2000 6.587.166 30.82%
2001 2.977.989 -121.2%
2002 7.013.006 57.54%
2003 4.917.602 -42.61%
2004 2.488.062 -97.65%
2005 12.500.430 80.1%
2006 703.500 -1676.89%
2007 21.977.178 96.8%
2008 5.554.642 -295.65%
2009 5.323.273 -4.35%
2010 25.063.989 78.76%
2011 17.918.707 -39.88%
2012 21.230.763 15.6%
2013 18.031.124 -17.75%
2014 18.208.914 0.98%
2015 -2.944.462 718.41%
2016 -108.623 -2610.74%
2017 27.166.000 100.4%
2018 32.747.000 17.04%
2019 26.408.000 -24%
2020 9.344.000 -182.62%
2021 16.429.000 43.12%
2022 16.942.000 3.03%
2023 2.668.000 -535.01%
2023 14.693.610 81.84%
2024 1.849.237 -694.58%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

HLS Therapeutics Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 3.932.334
1997 7.267.645 45.89%
1998 5.654.124 -28.54%
1999 6.145.008 7.99%
2000 985.214 -523.72%
2001 1.191.669 17.32%
2002 2.009.059 40.69%
2003 1.645.627 -22.08%
2004 1.503.985 -9.42%
2005 5.412.433 72.21%
2006 17.879.204 69.73%
2007 11.388.468 -56.99%
2008 10.581.758 -7.62%
2009 3.003.534 -252.31%
2010 2.875.540 -4.45%
2011 2.657.199 -8.22%
2012 2.023.461 -31.32%
2013 491.186 -311.95%
2014 41.349 -1087.93%
2015 158.000 73.83%
2016 314.175 49.71%
2017 179.000 -75.52%
2018 781.000 77.08%
2019 2.559.000 69.48%
2020 44.677.000 94.27%
2021 4.510.000 -890.62%
2022 10.148.000 55.56%
2023 27.000 -37485.19%
2023 192.466 85.97%
2024 15 -1374657.14%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

HLS Therapeutics Inc. Equity
Year Equity Growth
1996 8.309.838
1997 16.911.250 50.86%
1998 10.008.448 -68.97%
1999 14.223.277 29.63%
2000 12.476.636 -14%
2001 24.454.436 48.98%
2002 24.468.068 0.06%
2003 26.673.966 8.27%
2004 18.421.315 -44.8%
2005 30.018.942 38.63%
2006 30.724.090 2.3%
2007 50.091.891 38.66%
2008 28.334.428 -76.79%
2009 35.898.195 21.07%
2010 33.233.682 -8.02%
2011 32.561.214 -2.07%
2012 40.990.923 20.56%
2013 40.526.123 -1.15%
2014 46.752.407 13.32%
2015 26.026.706 -79.63%
2016 24.972.100 -4.22%
2017 180.382.000 86.16%
2018 158.489.000 -13.81%
2019 178.199.000 11.06%
2020 169.249.000 -5.29%
2021 160.736.000 -5.3%
2022 125.318.000 -28.26%
2023 97.197.152 -28.93%
2023 111.436.000 12.78%
2024 82.693.870 -34.76%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

HLS Therapeutics Inc. Assets
Year Assets Growth
1996 18.400.356
1997 40.950.384 55.07%
1998 27.815.688 -47.22%
1999 37.560.500 25.94%
2000 25.575.963 -46.86%
2001 30.372.972 15.79%
2002 28.636.322 -6.06%
2003 41.490.780 30.98%
2004 29.979.037 -38.4%
2005 44.194.937 32.17%
2006 49.245.024 10.26%
2007 77.991.517 36.86%
2008 45.861.955 -70.06%
2009 53.438.067 14.18%
2010 45.402.735 -17.7%
2011 46.009.794 1.32%
2012 49.678.839 7.39%
2013 54.814.654 9.37%
2014 60.170.046 8.9%
2015 26.598.880 -126.21%
2016 25.524.142 -4.21%
2017 384.646.000 93.36%
2018 306.425.000 -25.53%
2019 319.671.000 4.14%
2020 303.906.000 -5.19%
2021 275.905.000 -10.15%
2022 241.652.000 -14.17%
2023 207.990.386 -16.18%
2023 226.818.000 8.3%
2024 191.293.941 -18.57%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

HLS Therapeutics Inc. Liabilities
Year Liabilities Growth
1996 10.090.517
1997 24.039.133 58.02%
1998 17.807.239 -35%
1999 23.337.222 23.7%
2000 13.099.326 -78.16%
2001 5.918.536 -121.33%
2002 4.168.254 -41.99%
2003 14.816.814 71.87%
2004 11.557.722 -28.2%
2005 14.175.994 18.47%
2006 18.520.933 23.46%
2007 27.899.626 33.62%
2008 17.527.526 -59.18%
2009 17.539.872 0.07%
2010 12.169.052 -44.14%
2011 13.448.579 9.51%
2012 8.687.916 -54.8%
2013 14.288.531 39.2%
2014 13.417.638 -6.49%
2015 572.173 -2245.03%
2016 552.042 -3.65%
2017 204.264.000 99.73%
2018 147.936.000 -38.08%
2019 141.472.000 -4.57%
2020 134.657.000 -5.06%
2021 115.169.000 -16.92%
2022 116.334.000 1%
2023 110.793.233 -5%
2023 115.382.000 3.98%
2024 108.600.070 -6.24%

HLS Therapeutics Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.86
Net Income per Share
-0.76
Price to Earning Ratio
-3.55x
Price To Sales Ratio
1.45x
POCF Ratio
7.62
PFCF Ratio
7.64
Price to Book Ratio
1.04
EV to Sales
2.3
EV Over EBITDA
7.74
EV to Operating CashFlow
12.09
EV to FreeCashFlow
12.15
Earnings Yield
-0.28
FreeCashFlow Yield
0.13
Market Cap
0,09 Bil.
Enterprise Value
0,14 Bil.
Graham Number
6.67
Graham NetNet
-2.04

Income Statement Metrics

Net Income per Share
-0.76
Income Quality
-0.47
ROE
-0.26
Return On Assets
-0.13
Return On Capital Employed
-0.04
Net Income per EBT
1.22
EBT Per Ebit
3.2
Ebit per Revenue
-0.1
Effective Tax Rate
-0.22

Margins

Sales, General, & Administrative to Revenue
0.17
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.51
Operating Profit Margin
-0.1
Pretax Profit Margin
-0.32
Net Profit Margin
-0.39

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.35
Free CashFlow per Share
0.35
Capex to Operating CashFlow
0.01
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.07
Return on Tangible Assets
-0.44
Days Sales Outstanding
56.71
Days Payables Outstanding
163.27
Days of Inventory on Hand
116.6
Receivables Turnover
6.44
Payables Turnover
2.24
Inventory Turnover
3.13
Capex per Share
0

Balance Sheet

Cash per Share
1,02
Book Value per Share
2,60
Tangible Book Value per Share
-1.69
Shareholders Equity per Share
2.6
Interest Debt per Share
2.91
Debt to Equity
1
Debt to Assets
0.43
Net Debt to EBITDA
2.87
Current Ratio
2.02
Tangible Asset Value
-0,05 Bil.
Net Current Asset Value
-0,06 Bil.
Invested Capital
163822975
Working Capital
0,03 Bil.
Intangibles to Total Assets
0.71
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
9434656.5
Debt to Market Cap
0.96

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

HLS Therapeutics Inc. Dividends
Year Dividends Growth
2010 0
2013 0 0%
2014 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

HLS Therapeutics Inc. Profile

About HLS Therapeutics Inc.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

CEO
Mr. Craig Stuart Millian M.B.A
Employee
91
Address
10 Carlson Court
Etobicoke, M9W 6L2

HLS Therapeutics Inc. Executives & BODs

HLS Therapeutics Inc. Executives & BODs
# Name Age
1 Dave Mason
Investor Relations Officer
70
2 Dr. Jason A. Gross Pharm.D.
Vice President of Scientific Affairs
70
3 Mr. Brian T. Walsh
Chief Commercial Officer
70
4 Mr. Craig Stuart Millian M.B.A.
Chief Executive Officer & Director
70
5 Mr. Ryan C. Lennox B.A., J.D.
Senior Vice President of Legal, HR & Compliance and Corporate Secretary
70
6 Mr. John Hanna CPA, CGA, M.B.A.
Chief Financial Officer & Non-Independent Director
70
7 Mr. David Spence
Vice President & Corporate Controller
70

HLS Therapeutics Inc. Competitors